Ruxolitinib

Also known as: INCB018424, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(βR)-1H-pyrazole-1-propanenitrile, Jakafi

Ruxolitinib (CAS 941678-49-5) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C17H18N6 and a molecular weight of 306.365 g/mol. Key properties include a boiling point of 592.6±50.0 °C at 760 mmHg, a density of 1.4±0.1 g/cm3 and a flash point of 312.2±30.1 °C. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 941678-49-5
Jingsj CID: J-1955140-7
Molecular Formula: C₁₇H₁₈N₆
Molecular Weight: 306.365 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Boiling Point	592.6±50.0 °C at 760 mmHg
Density	1.4±0.1 g/cm3
Flash Point	312.2±30.1 °C
Exact Mass	306.159302
PSA	83.18000
LogP	1.69
Vapor Pressure	0.0±1.7 mmHg at 25°C
Refractive Index	1.747
Storage Conditions	2-8°C

Activity & Biological Data

Target	JAK2:2.8 nM (IC50) JAK1:3.3 nM (IC50) Tyk2:19 nM (IC50) JAK3:428 nM (IC50)
Additional Information	[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807. [3]. Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98.

Target

JAK2:2.8 nM (IC50) JAK1:3.3 nM (IC50) Tyk2:19 nM (IC50) JAK3:428 nM (IC50)

Additional Information

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807. [3]. Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98.

Frequently Asked Questions

What is the CAS number of Ruxolitinib?

The CAS number of Ruxolitinib is 941678-49-5.

What are the molecular formula and molecular weight of Ruxolitinib?

Ruxolitinib has molecular formula C17H18N6 and molecular weight 306.365 g/mol.

What are the upstream and downstream products of Ruxolitinib?

For Ruxolitinib, Upstream Products: (R)-3-cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine, 4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine; Downstream Products: Ruxolitinib maleate, Ruxolitinib phosphate.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Ruxolitinib (CAS 941678-49-5)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1955140-7 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.